Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial Meeting Abstract
| Authors: | Smit, E. F.; Felip, E.; Uprety, D.; Nakagawa, K.; Paz-Ares, L.; Pacheco, J.; Li, B. T.; Planchard, D.; Baik, C.; Goto, Y.; Murakami, H.; Saltos, A.; Saxena, K.; Shiga, R.; Cheng, Y.; Yan, Q.; Feng, W.; Jänne, P. A. |
| Abstract Title: | Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial |
| Meeting Title: | ESMO Congress 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2022 Sep 9-13 |
| Meeting Location: | Paris, France |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-09-01 |
| Start Page: | S994 |
| End Page: | S995 |
| Language: | English |
| ACCESSION: | WOS:000866211601243 |
| DOI: | 10.1016/j.annonc.2022.07.1103 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 975P -- Source: Wos |
